Clinical Trial Update: Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

View source ↗

Summary

Clinical trial update shows recruitment for a study evaluating secukinumab (Cosentyx) for moderate to severe hidradenitis suppurativa. The sponsor is Peking Uni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Peking Union Medical College | Conditions: Hidradenitis Suppurativa (HS) | Status: RECRUITING